医疗补助扩张对炎症性肠病和医疗保健利用率的影响
Brittany E Levy1, Anthony A Mangino2, Jennifer T Castle1
1University of Kentucky Department of Surgery, 780 Rose Street, Lexington, KY, 40536, USA.
American journal of surgery
|January 28, 2024
概括
肯塔基州的医疗补助扩张减少了炎症性肠病 (IBD) 的住院和急诊,增加了门诊护理. 这改善了IBD患者获得预防服务的机会,并降低了IBD患者的医疗保健成本.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 公共卫生政策 公共卫生政策
- 胃肠病学 胃肠病学
背景情况:
- 肯塔基州早期采用医疗补助扩张导致无保险费率大幅下降.
- 该研究调查了医疗补助扩张对炎性肠病 (IBD) 患者医疗保健利用的影响.
研究的目的:
- 评估医疗补助扩张如何影响IBD患者的选择性医疗保健使用和紧急治疗.
- 评估医院住院,门诊和急诊访问模式在Medicaid扩张后的变化.
主要方法:
- 在肯塔基州从2009年至2020年期间,利用了医院住院患者出院和门诊服务数据库 (HIDOSD) 进行IBD接触.
- 在医疗补助扩张之前和之后,比较人口统计变量和医疗保健利用模式.
主要成果:
- 分析了3386个扩张前和24255个扩张后IBD遭遇.
- 医院住院率 (47.7%至8.4%) 和急诊次数 (36.7%至11.4%) 显著下降.
- 报告指出,门诊病人的数量增加 (52.3%至91.6%),通过临床转诊的入院人数增加,通过急诊室的入院人数减少. 医院费用和住院时间也减少了.
结论:
- 医疗补助扩张改善了IBD患者获得预防护理的机会.
- 减少紧急护理利用率导致医院成本降低.
- 增加的选择性护理途径和门诊访问意味着IBD医疗保健的积极转变.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease I: Ulcerative Colitis
186
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
186
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166


